Research Article | Volume: 5, Issue: 11, November, 2015
Research Article | Volume: 5, Issue: 11, November, 2015
Epidermal Growth Factor Receptor (EGFR) is one of the four members of the Human Epidermal Receptor (HER) family, which is deregulated and over expressed in platinum resistant ovarian cancer. Thus, targeting EGFR receptor along with platinum drugs is one of the major strategies to increase the platinum drug sensitivity. That’s why, in this study, we aimed to investigate the inhibitory activity and binding site analysis of indole-3-carbinol and its active metabolite 3,3'-diindolylmethane by using molecular simulation studies, also metabolic profile had been investigated by SOM prediction. The 3,3'-diindolylmethane showed significant inhibitory activity and binding energy comparing to indole-3-carbinol, also it processed lower toxicity and will undergo aromatic hydroxylation due its high intrinsic activity and Fe accessibility. Though our research study supports previous reports of EGFR inhibition, further in vivo study is necessary for validation of toxicological and pharmacokinetic study. However, the current work tries to address most of the variables in the dynamic drug design process by In silico study in order to boost the potentiality of the selected molecule to serve as good leads in terms of optimum pharmacokinetic and toxicological attributes.
Dash R, Hosen SMZ, Karim MR, Kabir MSH, Hossain MM, Junaid M, Islam A, Paul A, Khan MA. In silico analysis of indole3-carbinol and its metabolite DIM as EGFR tyrosine kinase inhibitors in platinum resistant ovarian cancer vis a vis ADME/T property analysis. J App Pharm Sci, 2015; 5 (11): 073-078.
Year
Month
Review on Biological Activities of 1,3,4-Thiadiazole Derivatives
Arvind k. Singh, Geeta Mishra, Kshitiz JyotiDocking and ADME/T analysis of silibinin as a potential inhibitor of EGFR kinase for ovarian cancer therapy